Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines

Full text
Author(s):
Gelaleti, Gabriela Bottaro ; Bonin, Thaiz Ferraz ; Maschio-Signorini, Larissa Bazela ; Moschetta, Marina Gobbe ; Jardim-Perassi, Bruna Victorasso ; Calvinho, Guilherme Berto ; Facchini, Mariana Castilho ; Viloria-Petit, Alicia M. ; Pires de Campos Zuccari, Debora Aparecida
Total Authors: 9
Document type: Journal article
Source: Life Sciences; v. 183, p. 98-109, AUG 15 2017.
Web of Science Citations: 7
Abstract

Mammary tumorigenesis can be modulated by melatonin, which has oncostatic action mediated by multiple mechanisms, including the inhibition of the activity of transcription factors such as NF-kappa B and modulation of interleukins (ILs) expression. IL-25 is an active cytokine that induces apoptosis in tumor cells due to differential expression of its receptor (IL-17RB). IL-17B competes with IL-25 for binding to IL-17RB in tumor cells, promoting tumorigenesis. This study purpose is to address the possibility of engaging IL-25/IL-17RB signaling to enhance the effect of melatonin on breast cancer cells. Breast cancer cell lines were cultured monolayers and 3D structures and treated with melatonin, IL-25, silL-17B, each alone or in combination. Cell viability, gene and protein expression of caspase-3, cleaved caspase-3 and VEGF-A were performed by qPCR and immunofluorescence. In addition, an apoptosis membrane array was performed in metastatic cells. Treatments with melatonin and IL-25 significantly reduced tumor cells viability at 1 mM and 1 ng/mL, respectively, but did not alter cell viability of a non-tumorigenic epithelial cell line (MCF-10A). All treatments, alone and combined, significantly increased cleaved caspase-3 in tumor cells grown as monolayers and 3D structures (p < 0.05). Semi-quantitative analysis of apoptosis pathway proteins showed an increase of CYTO-C, DR6, IGFBP-3, IGFBP-5, IGFPB-6,IGF-1, IGF-1R, Livin, P21, P53, TNFRII, XIAP and hTRA proteins and reduction of caspase-3 (p < 0.05) after melatonin treatment. All treatments reduced VEGF-A protein expression in tumor cells (p < 0.05). Our results suggest therapeutic potential, with oncostatic effectiveness, pro-apoptotic and anti-angiogenic properties for melatonin and IL-25-driven signaling in breast cancer cells. (C) 2017 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 12/06098-0 - Modulation of interleukin 17b and 25 activity associated with melatonin as inductor of apoptosis in cell culture of mammary neoplasms
Grantee:Debora Aparecida Pires de Campos Zuccari
Support type: Regular Research Grants
FAPESP's process: 12/02128-1 - Modulation of interleukin 17b and 25 activity associated with melatonin as inductor of apoptosis in cell culture of mammary neoplasms
Grantee:Gabriela Bottaro Gelaleti
Support type: Scholarships in Brazil - Doctorate